Search Result

Results for "

CLL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (2) Akt (2) Antibiotic (1) Apoptosis (30) Arp2/3 Complex (1) Autophagy (1) Bacterial (1) Bcl-2 Family (3) Bcr-Abl (2) BMX Kinase (1) Btk (9) Carnitine Palmitoyltransferase (CPT) (3) Casein Kinase (6) Caspase (1) CCR (1) CD20 (1) CDK (1) CXCR (1) DNA/RNA Synthesis (1) EGFR (2) Endogenous Metabolite (9) Epigenetic Reader Domain (3) ERK (2) FGFR (1) FLT3 (3) Fungal (2) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (3) JNK (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) MHC (1) Mitochondrial Metabolism (3) Mitosis (1) Molecular Glues (1) NF-κB (3) Orthopoxvirus (7) Parasite (1) PDHK (1) PI3K (7) PKA (1) PKC (7) PROTAC-Linker Conjugates for PAC (1) PROTACs (6) Reactive Oxygen Species (ROS) (1) Reference Standards (11) SF3B1 (2) Syk (7) TNF Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (7) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (64) Cardiovascular Disease (7) Infection (9) Inflammation/Immunology (11) Neurological Disease (2)
Oligonucleotides:	CpG ODNs (1) Antisense Oligonucleotides (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13502

Mitoxantrone Maximum Cited Publications 46 Publications Verification Mitozantrone; NSC 301739	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-17600

Acalabrutinib 30+ Cited Publications Calquence; ACP-196	Btk	Inflammation/Immunology Cancer
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1334A

Perhexiline maleate 5+ Cited Publications	Carnitine Palmitoyltransferase (CPT) Mitochondrial Metabolism Apoptosis	Cardiovascular Disease Cancer
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .

HY-13502A

Mitoxantrone dihydrochloride Maximum Cited Publications 46 Publications Verification Mitozantrone dihydrochloride; NSC 301739 dihydrochloride	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-12279

Umbralisib 5 Publications Verification TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .

HY-16466

Spliceostatin A	SF3B1	Cancer
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .

HY-146237

Golcadomide CC-99282	Ligands for E3 Ligase Molecular Glues	Cancer
Golcadomide (CC-99282) is a potent and orally active CRBN E3 ligase modulator (CELMoD). Golcadomide interacts with the CRL4 CRBN E3 ubiquitin ligase substrate receptor CRBN, inducing the recruitment and ubiquitin-mediated proteasomal degradation of the transcription factors Ikaros and Aiolos. Golcadomide shows potential for research in cancer-related fields, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) .

HY-13599

Cladribine 5+ Cited Publications 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA	Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

HY-B1334

Perhexiline 5+ Cited Publications	Carnitine Palmitoyltransferase (CPT) Mitochondrial Metabolism Apoptosis	Cardiovascular Disease Cancer
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .

HY-12445

Asnuciclib 2 Publications Verification CDKI-73; LS-007	CDK Apoptosis	Inflammation/Immunology Cancer
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .

HY-P9961

Ofatumumab GSK1841157; OMB-157	CD20	Cancer
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .

HY-N6727

Gliotoxin 2 Publications Verification Aspergillin	Apoptosis PKA NF-κB Bacterial Fungal Antibiotic	Infection Inflammation/Immunology Cancer
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .

HY-14951

Firategrast 5+ Cited Publications SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .

HY-108052

Delphinidin 3-glucoside chloride 1 Publications Verification Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	EGFR Apoptosis Akt	Cardiovascular Disease Cancer
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-114989

Fluorizoline 3 Publications Verification	Apoptosis	Cancer
Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner .

HY-100867A

Mivavotinib monohydrochloride TAK-659 monohydrochloride; CB-659 monohydrochloride	Syk FLT3	Cancer
TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-12974

PRT-060318 4 Publications Verification PRT318	Syk Apoptosis	Inflammation/Immunology Cancer
PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC₅₀ of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .

HY-174864

JP-163-16	PROTACs NF-κB Apoptosis	Cancer
JP-163-16 is a RelA/p65 PROTAC degrader. JP-163-16 selectively reduces the expression of RelA/p65 in a proteasome-dependent manner in cells. JP-163-16 can induce cell apoptosis by inhibiting the NF-κB signaling pathway. JP-163-16 can be used for research on RelA/p65-dependent tumours, such as chronic lymphocytic leukaemia (CLL). (Pink: RelA/p65 Ligand (HY-174865); Blue: CRBN Ligand (HY-A0003); Black: Linker; CRBN Ligand+Linker (HY-160241)) .

HY-122562

MT-802 4 Publications Verification	PROTACs Btk	Cancer
MT-802 is a BTK PROTAC degrader. MT-802 degrades wild-type BTK (DC₅₀ = 14.6 nM) and BTK mutants including E41K, C481S (DC₅₀ = 14.9 nM), C481R, C481Y, C481T, C481F, L528W, and inhibits their Y223 phosphorylation. BI-4732 can be used for the study of Ibrutinib (HY-10997)-resistant chronic lymphocytic leukemia (CLL). (Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-141371), E3 ligase ligand-linker conjugate (HY-176340)) .

HY-P991224

CAP-100	CCR	Inflammation/Immunology Cancer
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-18676B

ILK-IN-2 OSU-T315 analog	Integrin Autophagy Apoptosis Caspase PDHK	Cancer
ILK-IN-2 (OSU-T315 analog) is an oral PDK2 inhibitor and also an ILK inhibitor, with an IC₅₀ of 0.6 μM. ILK-IN-2 induces cell autophagy and apoptosis, showing anti-tumor activity. ILK-IN-2 directly abolishes AKT activation by preventing AKT from translocating to lipid rafts, triggering Caspase-dependent apoptosis in chronic lymphocytic leukemia (CLL) and extending the lifespan in TCL1 mouse models .

HY-12279C

Umbralisib hydrochloride 5 Publications Verification TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 ^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-N6744

Chaetoglobosin A	Apoptosis Endogenous Metabolite Fungal Parasite Arp2/3 Complex	Infection Cancer
Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia .

HY-138632

PROTAC BRD4 Degrader linker conjugate	PROTACs Epigenetic Reader Domain PROTAC-Linker Conjugates for PAC	Cancer
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC₅₀ values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n

HY-139481

TL-895 1 Publications Verification	Btk BMX Kinase Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology Cancer
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC₅₀: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC₅₀ = 1.6 nM) and TXK with IC₅₀ within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC₅₀: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .

HY-171499

Cenersen EL625	MDM-2/p53	Cancer
Cenersen (EL625) is an oligonucleotide targeting TP53. Cenersen can eliminate the activity of TP53 gain-of-function mutants and increase the sensitivity of lymphoma cells to cytotoxic chemotherapy in vitro. Cenersen can be used for the study of chronic lymphocytic leukemia (CLL) .

HY-12736A

GSK143 dihydrochloride 1 Publications Verification	Syk ERK	Inflammation/Immunology Cancer
GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC₅₀=7.1) . GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-17600S

Acalabrutinib-d4 ACP-196-d₄	Btk	Cancer
Acalabrutinib-d₄ (ACP-196-d₄) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor . Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12908

Bcl-xL antagonist 2	Bcl-2 Family Apoptosis	Cancer
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-X_L with an IC₅₀ and K_i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .

HY-160966

PROTAC BTK Degrader-10	PROTACs Btk	Cancer
PROTAC BTK Degrader-10 (Example 1P) is a PROTAC degrader for BTK. PROTAC BTK Degrader-10 can be used for research of chronic lymphocytic leukemia (CLL) (Pink: ligand for target protein (HY-170758); Black: linker (HY-W392857); Blue: ligand for E3 ligase Cereblon (HY-W733176))

HY-100867

Mivavotinib TAK-659; CB-659	Syk FLT3	Cancer
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-177058

DSP30	Toll-like Receptor (TLR) Mitosis	Inflammation/Immunology
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .

HY-175342

FCN-338 LOXO-338	Bcl-2 Family	Cancer
FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC₅₀ of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL .

HY-12736

GSK143	Syk ERK	Inflammation/Immunology Cancer
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC₅₀=7.1) . GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-114461

FD-895	DNA/RNA Synthesis Apoptosis	Cancer
FD-895 is a spliceosome modulator derived from a polyketide natural product, targeting the SF3b subunit of the spliceosome. FD-895 possesses core biological activities for regulating RNA splicing (intron retention, alternative splicing) and inducing apoptosis of cancer cells. FD-895 can be used for the research of cancer, such as chronic lymphocytic leukemia (CLL) .

HY-177276

FGFR-IN-22	FGFR	Cancer
FGFR-IN-22 (Compound 23) is a FGFR inhibitor with IC₅₀s of 0.631, 1.26, 0.851 and 1 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-22 effectively inhibits cell proliferation that depends on the FGFR1 and FGFR3 signaling pathway. FGFR-IN-22 can be used for cancers such as chronic lymphocytic leukemia (CLL) research .

HY-17600R

Acalabrutinib (Standard) ACP-196 (Standard)	Reference Standards Btk	Cancer
Acalabrutinib (Standard) is the analytical standard of Acalabrutinib. This product is intended for research and analytical applications. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL) . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P991562

MDX-1411	Transmembrane Glycoprotein	Cancer
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology Cancer
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .

HY-163607

SpiD3	Apoptosis NF-κB	Cancer
SpiD3, a spirocyclic dimer, is an anticancer agent. SpiD3 markedly inhibits malignant B-cell proliferation and suppressed NF-κB activation independent of TME-associated stimuli. SpiD3 induces apoptosis and inhibits protein synthesis in chronic lymphocytic leukemia cells. SpiD3 can be used for study of chronic lymphocytic leukemia (CLL) .

HY-168983

Lonitoclax	Bcl-2 Family	Cancer
Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .

HY-138635

PROTAC BRD4 Degrader-12	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.39 nM and 0.24 nM, respectively .

HY-138633

PROTAC BRD4 Degrader-10	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 1.3 nM and 18 nM, respectively .

HY-108052R

Delphinidin 3-glucoside chloride (Standard) Delphinidin 3-O-glucoside chloride (Standard); Delphinidin 3-O-β-glucoside chloride (Standard)	Reference Standards EGFR Apoptosis Akt	Cardiovascular Disease Cancer
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-13599R

Cladribine (Standard) 2-Chloro-2′-deoxyadenosine (Standard); CldAdo (Standard); 2CdA (Standard)	Reference Standards Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (Standard) is the analytical standard of Cladribine. This product is intended for research and analytical applications. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

HY-W757743

Acalabrutinib-d3 ACP-196-d₃	Isotope-Labeled Compounds	Others
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

Cat. No.	Product Name	Target	Research Area	Image

HY-P9961

Ofatumumab GSK1841157; OMB-157	CD20	Cancer
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .

HY-P991224

CAP-100	CCR	Inflammation/Immunology Cancer
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P991562

MDX-1411	Transmembrane Glycoprotein	Cancer
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology Cancer
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .

HY-P991590

1D09C3	MHC Apoptosis JNK Reactive Oxygen Species (ROS)	Cancer
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13502

Mitoxantrone Maximum Cited Publications 46 Publications Verification Mitozantrone; NSC 301739	Infection Quinones Classification of Application Fields Anthraquinones Endogenous metabolite Disease Research Fields Source Classification Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502A

Mitoxantrone dihydrochloride Maximum Cited Publications 46 Publications Verification Mitozantrone dihydrochloride; NSC 301739 dihydrochloride	Infection Quinones Classification of Application Fields Anthraquinones Endogenous metabolite Disease Research Fields Source Classification Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-N6727

Gliotoxin 2 Publications Verification Aspergillin	Anti-inflammation/Immunoregulatory Classification of Application Fields Antibacterial Disease Research Other Antibiotics Biological Pesticide Research Agricultural Research Infection Microorganisms Antibiotics Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis PKA NF-κB Bacterial Fungal Antibiotic
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .

HY-108052

Delphinidin 3-glucoside chloride 1 Publications Verification Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	Malvaceae Anthocyans Flavonoids Microorganisms Classification of Application Fields Hibiscus sabdariffa Linn. Plants Disease Research Fields Source Classification Cancer	EGFR Apoptosis Akt
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-N6744

Chaetoglobosin A	Infection Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Marine natural products Endogenous metabolite Marine microorganism Disease Research Fields Indole Alkaloids Source Classification	Apoptosis Endogenous Metabolite Fungal Parasite Arp2/3 Complex
Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia .

HY-108052R

Delphinidin 3-glucoside chloride (Standard) Delphinidin 3-O-glucoside chloride (Standard); Delphinidin 3-O-β-glucoside chloride (Standard)	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Hibiscus sabdariffa Linn. Plants Source Classification	Reference Standards EGFR Apoptosis Akt
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-13502B

Mitoxantrone diacetate Mitozantrone diacetate; NSC 301739 diacetate	Infection Quinones Classification of Application Fields Anthraquinones Endogenous metabolite Disease Research Fields Source Classification Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone diacetate is a potent topoisomerase II inhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone diacetate induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity . Mitoxantrone diacetate also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502AR

Mitoxantrone dihydrochloride (Standard) Mitozantrone dihydrochloride (Standard); NSC 301739 dihydrochloride (Standard)	Quinones Structural Classification Anthraquinones Endogenous metabolite Source Classification	Reference Standards Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone (dihydrochloride) (Standard) is the analytical standard of Mitoxantrone (dihydrochloride). This product is intended for research and analytical applications. Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502R

Mitoxantrone (Standard) Mitozantrone (Standard); NSC 301739 (Standard)	Quinones Structural Classification Anthraquinones Endogenous metabolite Source Classification	Reference Standards Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone (Standard) is the analytical standard of Mitoxantrone. This product is intended for research and analytical applications. Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-113382R

N-Methylhydantoin (Standard) 1-Methylhydantoin (Standard)	Alkaloids Structural Classification Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Species:	Human (11) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	SUMO (1) His (9) Tag Free (2) Avi (2) GST (1) Fc (2)
Source:	HEK293 (8) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78623

	CLEC12A/MICL Protein, Rat (HEK293, His) CLEC12A; MICL; CLL-1; CLL1; DCAL2; DCAL-2; CD371	Rat	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. CLEC12A/MICL Protein, Rat (HEK293, His) is the recombinant rat-derived CLEC12A/MICL protein, expressed by HEK293 , with N-His labeled tag. The total length of CLEC12A/MICL Protein, Rat (HEK293, His) is 205 a.a., with molecular weight of 32-45 kDa.

HY-P77631

	CLEC12A/MICL Protein, Human (HEK293, Fc) MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2	Human	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. CLEC12A/MICL Protein, Human (HEK293, Fc) is the recombinant human-derived CLEC12A/MICL protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P77903

	CLEC12A/MICL Protein, Cynomolgus (HEK293, His) MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2	Cynomolgus	HEK293
	CLEC12A/MICL Protein is a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. CLEC12A is a cell surface receptor known to regulate signaling cascades and facilitate the tyrosine phosphorylation of target MAP kinases. It interacts with PTPN6 and PTPN11, indicating its involvement in intricate cellular signaling processes. CLEC12A/MICL Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CLEC12A/MICL protein, expressed by HEK293 , with N-His labeled tag.

HY-P77905

	CLEC12A/MICL Protein, Mouse (HEK293, His) MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2	Mouse	HEK293
	CLEC12A/MICL protein acts as a cell surface receptor, facilitating tyrosine phosphorylation of MAP kinases and modulating signaling cascades. It interacts with PTPN6 and PTPN11, key proteins in signaling pathways. CLEC12A/MICL Protein, Mouse (HEK293, His) is the recombinant mouse-derived CLEC12A/MICL protein, expressed by HEK293 , with N-His labeled tag.

HY-P77633

	CLEC12A/MICL Protein, Human (Biotinylated, HEK293, His-Avi) MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2	Human	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. CLEC12A/MICL Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CLEC12A/MICL protein, expressed by HEK293 , with C-Avi, N-His labeled tag.

HY-P77634

	CLEC12A/MICL Protein, Human (Biotinylated, HEK293, Fc-Avi) MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2	Human	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. CLEC12A/MICL Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CLEC12A/MICL protein, expressed by HEK293 , with N-hFc, N-Avi labeled tag.

HY-P702576

	YTHDF2 Protein, Human (His) DF2; CLL-associated antigen KW-14; High-glucose-regulated protein 8; Renal carcinoma antigen NY-REN-2	Human	E. coli
	YTHDF2 Protein, Human (His) is the recombinant human-derived YTHDF2, expressed by E. coli , with C-6*His labeled tag. ,

HY-P76267

	CLEC12A/MICL Protein, Human (HEK293, His) C-type lectin domain family 12 member A; CLL-1; DCAL-2; MICL; CD371	Human	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. CLEC12A/MICL Protein, Human (HEK293, His) is the recombinant human-derived CLEC12A/MICL protein, expressed by HEK293 , with N-His labeled tag.

HY-P78653

	FITC-Labeled CLEC12A/MICL Protein, Human (HEK293, His, solution) C-type lectin domain family 12 member A; CLL-1; DCAL-2; MICL; CD371	Human	HEK293
	CLEC12A/MICL (C-type lectin domain family 12 member A/myelosuppressive C-type lectin-like receptor) is a cell surface receptor that acts as a modulator of signaling cascades, specifically promoting target MAP kinases Protease. FITC-Labeled CLEC12A/MICL Protein, Human (HEK293, His, solution) is the recombinant human-derived CLEC12A/MICL protein, expressed by HEK293 , with N-His labeled tag.

HY-P702575

	BCL6 Protein, Human B cell CLL/lymphoma 6; B cell lymphoma 6 protein; B-cell lymphoma 5 protein; B-cell lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.

HY-P72102

	BCL6 Protein, Human (GST) B cell CLL/lymphoma 6; B cell lymphoma 6 protein; B-cell lymphoma 5 protein; B-cell lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag.

HY-P71340

	STUB1 Protein, Human 2 Publications Verification E3 Ubiquitin-Protein Ligase CHIP; Antigen NY-CO-7; CLL-Associated Antigen KW-8; Carboxy Terminus of Hsp70-Interacting Protein; STIP1 Homology and U Box-Containing Protein 1; STUB1; CHIP	Human	E. coli
	STUB1 protein is an E3 ubiquitin protein ligase that cooperates with ATXN3 to regulate ubiquitin chain length on substrates and prevent chain extension. It ubiquitinates NOS1 through Hsp70/Hsp40 and regulates chaperone complexes (Hsp70, Hsc70, Hsp90). STUB1 Protein, Human is the recombinant human-derived STUB1 protein, expressed by E. coli , with tag free.

HY-P705928

	STUB1 Protein, Human (His) E3 Ubiquitin-Protein Ligase CHIP; Antigen NY-CO-7; CLL-Associated Antigen KW-8; Carboxy Terminus of Hsp70-Interacting Protein; STIP1 Homology and U Box-Containing Protein 1; STUB1; CHIP	Human	E. coli
	STUB1 protein is an E3 ubiquitin protein ligase that cooperates with ATXN3 to regulate ubiquitin chain length on substrates and prevent chain extension. It ubiquitinates NOS1 through Hsp70/Hsp40 and regulates chaperone complexes (Hsp70, Hsc70, Hsp90). STUB1 Protein, Human (His) is the recombinant human-derived STUB1 protein, expressed by E. coli , with His tag.

HY-P71608

	TGS1 Protein, Human (His-SUMO) Cap specific guanine N2 methyltransferase; Cap-specific guanine-N2 methyltransferase; CLL associated antigen KW 2; CLL-associated antigen KW-2; DKFZp762A163; FLJ22995; HCA137; Hepatocellular carcinoma associated antigen 137; Hepatocellular carcinoma-associated antigen 137; NCOA6IP; Nuclear receptor coactivator 6 interacting protein; Nuclear receptor coactivator 6-interacting protein; PIMT; PIPMT; PRIP interacting protein PIPMT; PRIP interacting protein with methyltransferase domain; PRIP interacting protein with methyltransferase motif; PRIP-interacting protein with methyltransferase motif; SEREX defined; TGS 1; Tgs1; TGS1_HUMAN; Trimethylguanosine synthase; Trimethylguanosine synthase homolog (S. cerevisiae); Trimethylguanosine synthase homolog	Human	E. coli
	TGS1 protein catalyzes the conversion of the 7-monomethylguanosine (m(7)G) cap of small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) into 2, 2,7-trimethylguanosine (m( 2,2,7)G) Cap structure. The enzyme shows specificity for guanine, with N7 methylation occurring before N2 methylation during the modification process. TGS1 Protein, Human (His-SUMO) is the recombinant human-derived TGS1 protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17600S

Acalabrutinib-d4
Acalabrutinib-d₄ (ACP-196-d₄) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor . Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-13502AS

Mitoxantrone-d8 dihydrochloride

Mitoxantrone-d₈ dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502AS1

Mitoxantrone-d8 hydrochloride

Mitoxantrone-d₈ (hydrochloride) (Mitozantrone-d₈ (hydrochloride)) is deuterium labeled Mitoxantrone (dihydrochloride). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

Host:	Mouse (8) Rabbit (8)
Reactivity:	Human (16) Mouse (2)
Application:	IHC-P (8) ICC/IF (7) IF-Tissue (2) IP (2) IHC-F (2) WB (10) FC (7) ELISA (5)
Isotype:	IgG (10) IgG1 (1) IgG2a (2)
Conjugation:	Non-conjugated (16) Biotin (2)
Clonality:	Monoclonal (12) Recombinant (5)
Modification:	Unmodified (12)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81674

	CLEC12A Antibody (YA1419) CLEC12A; MICL; CLL-1; CLL1; DCAL2; DCAL-2; CD371	FC, ELISA	Human
	CLEC12A Antibody (YA1419) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CLEC12A.

HY-P84992

	CLEC12A Antibody (YA4684) CLL1; MICL; CLL-1; DCAL-2; C-type lectin domain family 12 member A; CD371; CD371 nanobody;	ELISA	Human
	CLEC12A Antibody (YA4684) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CLEC12A.

HY-P84631

	CLEC12A Antibody (YA4328) CLEC12A; MICL; CD371; CLL-1; DCAL-2	WB, ICC/IF, FC, ELISA	Human
	CLEC12A Antibody (YA4328) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CLEC12A.

HY-P84631A

	CLEC12A Antibody (YA4328)(PBS only) CLEC12A; MICL; CD371; CLL-1; DCAL-2	WB, ICC/IF, FC, ELISA	Human
	CLEC12A Antibody (YA4328) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CLEC12A.

HY-P81443

	Bcl-10 Antibody (YA1188) BCL10; CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	IHC-P	Human
	Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

HY-P85051

	Bcl-10 Antibody (YA4743) BCL10; CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Bcl-10 Antibody (YA4743) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Bcl-10.

HY-P81443A

	Bcl-10 Antibody (YA1188)(PBS only) BCL10; CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	IHC-P	Human
	Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

HY-P86688

	Bcl-2 Antibody (YA6380) Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; B cell lymphoma 2; Bcl 2; Bcl-2; Bcl2; BCL2 protein; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; BCL2_HUMAN.	WB, IHC-P, IHC-F, IF-Tissue	Human
	Bcl-2 Antibody (YA6380) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

HY-P86712

	Bcl-2 Antibody (YA6404) Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; B cell lymphoma 2; Bcl 2; Bcl-2; Bcl2; BCL2 protein; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; BCL2_HUMAN.	WB, ICC/IF, FC	Human
	Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

HY-P86712A

	Bcl-2 Antibody (YA6404)(PBS only) Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; B cell lymphoma 2; Bcl 2; Bcl-2; Bcl2; BCL2 protein; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; BCL2_HUMAN.	WB, ICC/IF, FC	Human
	Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

HY-P85256

	PSIP1/LEDGF Antibody (YA4948) PSIP1; DFS70; LEDGF; PSIP2; PC4 and SFRS1-interacting protein; CLL-associated antigen KW-7; Dense fine speckles 70 kDa protein; DFS 70; Lens epithelium-derived growth factor; Transcriptional coactivator p75/p52	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human
	PSIP1/LEDGF Antibody (YA4948) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to PSIP1/LEDGF.

HY-P81282

	Ikaros Antibody (YA987) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	WB, IP	Human
	Ikaros Antibody (YA987) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Ikaros.

HY-P81282A

	Ikaros Antibody (YA988) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	IHC-P	Human
	Ikaros Antibody (YA988) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ikaros.

HY-P85524

	Ikaros(C-term) Antibody (YA5216) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros; zinc finger protein; IKAROS; IKAROS family zinc finger 1; Ikaros; Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1; Ikaros; zinc finger protein subfamily 1A 1; Zinc finger protein, subfamily 1A, member 1; ZNFN1A1.	WB, IP	Human
	Ikaros(C-term) Antibody (YA5216) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Ikaros(C-term).

HY-P81282AA

	Ikaros Antibody (YA988)(PBS only) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	IHC-P	Human
	Ikaros Antibody (YA988) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ikaros.

HY-P80095

	Ctip2 Antibody (YA488) ATL1 alpha antibody; ATL1 antibody; ATL1 beta antibody; ATL1 gamma antibody; ATL1-delta antibody; B-cell CLL/lymphoma 11B antibody; B-cell lymphoma/leukemia 11B antibody; BC11B_HUMAN antibody; BCL-11B antibody; Bcl11b antibody; BCL11B/TRDC fusion antibody; COUP TF interacting protein 2 antibody; Ctip 2 antibody; CTIP-2 antibody; CTIP2 antibody; hRIT1 alpha antibody; hRit1 antibody; Radiation induced tumor suppressor gene 1 antibody; Rit 1 antibody; zinc finger protein hRit1 alpha antibody; ZNF856B antibody	WB, ICC/IF, IHC-P, FC	Human, Mouse
	Ctip2 Antibody (YA488) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ctip2.